Sander Croes

930 total citations
46 papers, 687 citations indexed

About

Sander Croes is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Sander Croes has authored 46 papers receiving a total of 687 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Pulmonary and Respiratory Medicine, 20 papers in Oncology and 12 papers in Molecular Biology. Recurrent topics in Sander Croes's work include Lung Cancer Treatments and Mutations (22 papers), Lung Cancer Research Studies (7 papers) and Antibiotics Pharmacokinetics and Efficacy (7 papers). Sander Croes is often cited by papers focused on Lung Cancer Treatments and Mutations (22 papers), Lung Cancer Research Studies (7 papers) and Antibiotics Pharmacokinetics and Efficacy (7 papers). Sander Croes collaborates with scholars based in Netherlands, United States and United Kingdom. Sander Croes's co-authors include Ellen E. Stobberingh, Cees Neef, Patrick S. Beisser, Ruud H. Deurenberg, Leo Stolk, Kris Stevens, Léo H. Koole, Menno L. W. Knetsch, Frank de Vries and Roger J. M. Brüggemann and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Biomaterials.

In The Last Decade

Sander Croes

44 papers receiving 671 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sander Croes Netherlands	15	234	151	136	128	86	46	687
Chengyi Wang China	14	220 0.9×	110 0.7×	45 0.3×	54 0.4×	80 0.9×	76	673
Noha N. Salama United States	21	432 1.8×	212 1.4×	418 3.1×	111 0.9×	151 1.8×	41	1.5k
Akira Kawashima Japan	19	257 1.1×	172 1.1×	68 0.5×	79 0.6×	67 0.8×	88	1.0k
Yosuke Aoki Japan	21	307 1.3×	118 0.8×	44 0.3×	160 1.3×	89 1.0×	94	1.1k
Francesco Marchesi Italy	19	249 1.1×	274 1.8×	346 2.5×	69 0.5×	25 0.3×	79	1.1k
Rishi Jain United States	15	106 0.5×	98 0.6×	139 1.0×	50 0.4×	46 0.5×	62	685
Kana Matsumoto Japan	16	172 0.7×	240 1.6×	82 0.6×	26 0.2×	221 2.6×	74	726
Weihong Zhang China	20	236 1.0×	129 0.9×	219 1.6×	73 0.6×	19 0.2×	62	1.1k
Moustafa Sherief Moustafa Kuwait	16	214 0.9×	225 1.5×	35 0.3×	57 0.4×	82 1.0×	72	1.2k
Martin Becker Netherlands	21	303 1.3×	516 3.4×	127 0.9×	181 1.4×	56 0.7×	52	1.6k

Countries citing papers authored by Sander Croes

Since Specialization

Citations

This map shows the geographic impact of Sander Croes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sander Croes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sander Croes more than expected).

Fields of papers citing papers by Sander Croes

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sander Croes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sander Croes. The network helps show where Sander Croes may publish in the future.

Co-authorship network of co-authors of Sander Croes

This figure shows the co-authorship network connecting the top 25 collaborators of Sander Croes. A scholar is included among the top collaborators of Sander Croes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sander Croes. Sander Croes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Croes, Sander, Robin M.J.M. van Geel, Lizza Hendriks, et al.. (2025). Osimertinib Cost Minimization in Non‐Small Cell Lung Cancer (NSCLC) Treatment: Hypothesis Generation for a Population Pharmacokinetic Approach for Equivalent Dose Optimization of Osimertinib in Combination with Cobicistat. The Journal of Clinical Pharmacology. 65(12). 1687–1698.

Moes, Dirk Jan A. R., Jeroen J. M. A. Hendrikx, Henk‐Jan Guchelaar, et al.. (2024). Model-Informed Development of a Cost-Saving Dosing Regimen for Sacituzumab Govitecan. Targeted Oncology. 19(5). 789–796. 1 indexed citations

Hendriks, Lizza, Kristien Winckers, Yvonne Henskens, et al.. (2024). Proactive monitoring of drug–drug interactions between direct oral anticoagulants and small-molecule inhibitors in patients with non-small cell lung cancer. British Journal of Cancer. 131(3). 481–490. 1 indexed citations

Veerman, G., René J. Boosman, Ron H.J. Mathijssen, et al.. (2024). Osimertinib Plasma Trough Concentration in Relation to Brain Metastases Development in Patients With Advanced EGFR-Mutated NSCLC. JTO Clinical and Research Reports. 5(4). 100656–100656. 2 indexed citations

Heine, Rob ter, Michel M. van den Heuvel, Berber Piet, et al.. (2023). A Systematic Evaluation of Cost-Saving Dosing Regimens for Therapeutic Antibodies and Antibody-Drug Conjugates for the Treatment of Lung Cancer. Targeted Oncology. 18(3). 441–450. 8 indexed citations

Veerman, G., Marthe S. Paats, Vivianne C. G. Tjan‐Heijnen, et al.. (2023). Exploring the impact of patient‐specific clinical features on osimertinib effectiveness in a real‐world cohort of patients with EGFR mutated non‐small cell lung cancer. International Journal of Cancer. 154(2). 332–342. 7 indexed citations

Mathijssen, Ron H.J., Anne‐Marie C. Dingemans, Vivianne C. G. Tjan‐Heijnen, et al.. (2022). 1130P Real-world data of osimertinib (osi) for the treatment of metastatic epidermal growth factor receptor (EGFR+) non-small cell lung cancer (NSCLC) patients (pts), with a focus on age, body mass index (BMI) and trough levels. Annals of Oncology. 33. S1067–S1068. 1 indexed citations

Hendriks, Lizza, et al.. (2022). Pharmacokinetic boosting of osimertinib with cobicistat in patients with non-small cell lung cancer: The OSIBOOST trial. Lung Cancer. 171. 97–102. 12 indexed citations

Geurts, Sandra M. E., Sander Croes, Frans Erdkamp, et al.. (2021). Survival before and after the introduction of pertuzumab and T-DM1 in HER2-positive advanced breast cancer, a study of the SONABRE Registry. Breast Cancer Research and Treatment. 188(2). 571–581. 7 indexed citations

10.

Geel, Robin M.J.M. van, et al.. (2021). Development and validation of an HPLC–MS/MS method to simultaneously quantify alectinib, crizotinib, erlotinib, gefitinib and osimertinib in human plasma samples, using one assay run. Biomedical Chromatography. 35(12). e5224–e5224. 20 indexed citations

11.

Boosman, René J., Thomas P. C. Dorlo, Jacobus A. Burgers, et al.. (2021). Toxicity of pemetrexed during renal impairment explained—Implications for safe treatment. International Journal of Cancer. 149(8). 1576–1584. 12 indexed citations

12.

Geurts, Sandra M. E., Sander Croes, Birgit E. P. J. Vriens, et al.. (2019). A real-life study on the implementation and effectiveness of exemestane plus everolimus per hospital type in patients with advanced breast cancer. A study of the Southeast Netherlands Advanced Breast Cancer registry.. The Breast. 44. 46–51. 1 indexed citations

13.

Geel, Robin M.J.M. van, Anne‐Marie C. Dingemans, Leo Stolk, et al.. (2019). Validation of an analytical method using HPLC–MS/MS to quantify osimertinib in human plasma and supplementary stability results. Biomedical Chromatography. 34(4). e4771–e4771. 26 indexed citations

14.

Croes, Sander, Rein Posthuma, Hieronymus J. Derijks, et al.. (2019). Pharmacokinetically-guided dosing of pemetrexed in a patient with renal impairment and a patient requiring hemodialysis. Lung Cancer. 130. 156–158. 8 indexed citations

15.

Koornstra, Rutger H.T., Johanna H. M. Driessen, Bas van Vlijmen, et al.. (2018). The Impact of Dose and Simultaneous Use of Acid-Reducing Agents on the Effectiveness of Vemurafenib in Metastatic BRAF V600 Mutated Melanoma: a Retrospective Cohort Study. Targeted Oncology. 13(3). 363–370. 4 indexed citations

16.

Verduin, Maikel, Jaap Zindler, Rob L. H. Jansen, et al.. (2017). Use of Systemic Therapy Concurrent With Cranial Radiotherapy for Cerebral Metastases of Solid Tumors. The Oncologist. 22(2). 222–235. 20 indexed citations

17.

Brüggemann, Roger J. M., Leo Stolk, Frank de Vries, et al.. (2017). Development and validation of an analytical method using UPLC–MS/MS to quantify everolimus in dried blood spots in the oncology setting. Journal of Pharmaceutical and Biomedical Analysis. 149. 106–113. 27 indexed citations

18.

Driessen, Johanna H. M., Yolande C.A. Keulemans, Nielka P. van Erp, et al.. (2016). Use of incretin agents and risk of acute and chronic pancreatitis: A population‐based cohort study. Diabetes Obesity and Metabolism. 19(3). 401–411. 28 indexed citations

19.

Croes, Sander, et al.. (2014). Vancomycin Dosing in Neutropenic Patients. PLoS ONE. 9(11). e112008–e112008. 22 indexed citations

20.

Stevens, Kris, Sander Croes, Rinske Boersma, et al.. (2010). Hydrophilic surface coatings with embedded biocidal silver nanoparticles and sodium heparin for central venous catheters. Biomaterials. 32(5). 1264–1269. 87 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact